Board and Management
NovaBiotics is led by a highly experienced Board and Management team with a wealth of experience and an impressive track record of business development and product commercialisation in the pharmaceutical and healthcare industry.
Dr. Deborah O’Neil
Chief Executive Officer and Scientific Officer
A biotechnologist with over two decades of experience in the field of anti-infectives research & drug development.
Deborah founded NovaBiotics in 2004. She trained as an immunologist in internationally acclaimed laboratories (University College London, UC San Diego, University of Ghent) before moving to Aberdeen and developing the clinical and commercial potential of her antimicrobial technologies, spinning NovaBiotics out of the University of Aberdeen’s Rowett Research Institute. Deborah is a Director of the BEAM Alliance (Biotechs across Europe Against AntiMicrobial Resistance), sits on the Advisory Board of the Scottish Life Sciences Association and is also a member of the Life Sciences board of Opportunity North East. Deborah Chairs the Working Group of the Medicines Discovery Catapult-Cystic Fibrosis Trust syndicate on antimicrobials in CF. In 2019, Deborah was named amongst 20 women leaders in European Biotechnology and in 2018, amongst the 30 female Leaders in UK healthcare. Deborah was named as Ernst & Young’s UK Healthcare Products & services Entrepreneur of the Year in 2014.
Mr Bryan Bodek
Chairman of the Board
Mr Bryan Bodek joined NovaBiotics Board in 2009. He was previously Chairman of Trenchard Aviation and brings more than 30 years’ experience of advising public and private companies in all aspects of their business.
Bryan’s background is in corporate finance/company law and he has served on the boards of three public companies. He has significant experience in leading successful health care licensing/marketing deals and was a long serving Board member of the University of Manchester’s new technology spin out company.
Bryan was 2011 Ernst & Young U.K. Entrepreneur Of The year for business to business goods and services.
Mr Ian Townsend
Ian joined NovaBiotics Board in 2011
Ian has over 20 years experience in the medical device sector, co-founding orthopaedic manufacturing business, Eurocut Plc, which went on to become The Medical House Plc and was floated on AIM in 2000. After many years as the Chief Executive Ian became Chairman where he remained until the successful sale of Medical House Plc to Consort Plc in 2009.
Ian qualified as a Chartered Accountant in 1976 and worked with KPMG until 1979 when he set up his own practice in Harrogate. Ian is the founder and Chairman of Townsend Investments Ltd and Townsend Family Investments LLP.
Professor Andy Porter
Andy is Professor of Medical Biotechnology, University of Aberdeen and Director of the Scottish Biologics Facility. Andy is also CTO of the Elasmogen Ltd. Andy was the founder and CSO of Haptogen Ltd. until Wyeth Inc. acquired it, in October 2007. Andy also holds non-executive Board positions on a number of Scottish biotechnology companies including the Chair of Roslin Technologies Ltd and is Vice President for Business at the Royal Society of Edinburgh. In 2005 he was made the Ernst and Young Plc, UK Science and Technology Entrepreneur of the Year. Andy has helped to establish a portfolio of award winning cocktail bars and Langstane Liquor Ltd in 2015, Aberdeen’s first gin distillery for 100 years. Andy is a graduate of St Andrew’s University, Scotland.
Grant joined NovaBiotics Board in 2013.
He is a serial entrepreneur and Chartered Insurance Broker; most of his working life being in in the insurance and financial services sectors. Grant led the successful AIM listing of the Broker Network and its subsequent sales to The Towergate Partnership.
Grant remains a Non-executive Director of the Ellis Bates Group of companies, which he cofounded in 1980. Grant resigned from the Assured Fire & Security Company Ltd in June 2019, following the successful sale of the business. He also serves as a mentor to several small companies.